Invention Grant
- Patent Title: Fusion protein comprising IL13
-
Application No.: US17158785Application Date: 2021-01-26
-
Publication No.: US11312757B2Publication Date: 2022-04-26
- Inventor: Niels Eijkelkamp , Cornelis Erik Hack , Judith Prado Sanchez , Jelena Popov-{hacek over (C)}eleketić , Sabine Versteeg
- Applicant: Synerkine Pharma B.V.
- Applicant Address: NL Naarden
- Assignee: Synerkine Pharma B.V.
- Current Assignee: Synerkine Pharma B.V.
- Current Assignee Address: NL Naarden
- Agency: Wilson Sonsini Goodrich & Rosati
- Priority: NL2022982 20190419,NL2022984 20190419
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07K14/54 ; A61P25/02

Abstract:
The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and/or or neurodegeneration.
Public/Granted literature
- US20210214411A1 FUSION PROTEIN COMPRISING IL13 Public/Granted day:2021-07-15
Information query
IPC分类: